Leap Therapeutics is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research.
April 16, 2018Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting
March 27, 2018Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 23, 2018Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock
as of 2:11 PM ETApr 20, 2018
Data provided by Nasdaq. Minimum 15 minutes delayed.